BioVie (BIVI) Scheduled to Post Quarterly Earnings on Monday

BioVie (NASDAQ:BIVI) will be issuing its quarterly earnings data on Monday, April 22nd.

BioVie (NASDAQ:BIVI) last announced its quarterly earnings results on Monday, February 12th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.10.

BioVie Price Performance

Shares of BioVie stock opened at $0.49 on Friday. The company has a market cap of $19.42 million, a PE ratio of -0.42 and a beta of 0.79. BioVie has a 52 week low of $0.45 and a 52 week high of $8.69. The business has a 50 day moving average price of $0.79 and a 200-day moving average price of $1.84.

Institutional Investors Weigh In On BioVie

Large investors have recently added to or reduced their stakes in the business. UBS Group AG increased its holdings in BioVie by 284.2% during the 4th quarter. UBS Group AG now owns 3,565 shares of the company’s stock valued at $28,000 after purchasing an additional 2,637 shares during the period. Commonwealth Equity Services LLC boosted its position in shares of BioVie by 33.5% in the 1st quarter. Commonwealth Equity Services LLC now owns 16,255 shares of the company’s stock worth $131,000 after purchasing an additional 4,080 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in shares of BioVie by 2,706.5% in the 1st quarter. Tower Research Capital LLC TRC now owns 4,294 shares of the company’s stock worth $35,000 after purchasing an additional 4,141 shares in the last quarter. Wells Fargo & Company MN boosted its position in shares of BioVie by 162.3% in the 4th quarter. Wells Fargo & Company MN now owns 7,044 shares of the company’s stock worth $55,000 after purchasing an additional 4,359 shares in the last quarter. Finally, Bank of America Corp DE boosted its position in shares of BioVie by 33.3% in the 1st quarter. Bank of America Corp DE now owns 24,596 shares of the company’s stock worth $199,000 after purchasing an additional 6,138 shares in the last quarter. Institutional investors own 4.59% of the company’s stock.

BioVie Company Profile

BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.